Skip to main content
Premium Trial:

Request an Annual Quote

Nasdaq, Nanogen, Uniscience, Partek, Elan Pharmaceuticals, Ariadne Genomics, Biolytix, Affymetrix, Georgia Institute of Technology, BioForce Nanosciences

Premium
Nasdaq Notifies Nanogen of Delisting Status on Minimum Bid Price
 
The Nasdaq Stock Market has notified Nanogen that it may delist the company’s stock from the market due to failure to maintain a minimum bid price for 30 days, the company said last week.
 
The notification has no effect on Nanogen’s stock currently, but if Nanogen’s shares do not trade at or above $1 per share for a period of 10 consecutive days in the next six months the firm will receive written notification from Nasdaq that its shares will be delisted.
 
The company’s stock has been trading under $1 steadily since mid-September and closed Monday at $.57 a share.
 
If Nanogen is delisted in May it may transfer to the Nasdaq Capital Market, at which time it will receive another 180 days to comply with the minimum bid rule.
 
Nanogen recently announced that it would shutter its microarray business, lay off around 20 percent of its staff, and realign the company behind its real-time PCR and point-of-care testing units (see BAN 11/20/2007).
 

 
Uniscience to Market Partek's Software in Brazil
 
Biotech distributor Uniscience will market and sell Partek’s analysis software in Brazil, Partek said this week.
 
Under the agreement, Uniscience of São Paolo will sell Partek’s Genomics Suite, Discovery Suite, QSAR Solution, and Screener’s Solution products.
 
Financial terms of the agreement were not released.
 

 
Elan Pharma Licenses Ariadne's Software
 
Elan Pharmaceuticals has licensed Ariadne Genomics’ Pathway Studio software to support its therapeutics research for neurological and autoimmune diseases, Ariadne said last week.
 
Pathway Studio includes the ResNet database of functional relationships, which is used to interpret microarray data and for researching signaling networks, and MedScan, which is a tool that extracts pathway related information from research literature.
 
Financial terms of the agreement were not released.
 

 
Biolytix to Offer Affymetrix UK's GeneChip Arrays to European Clients
 
Swiss analytical services company Biolytix has bought an Affymetrix GeneChip instrument and has signed a service provider agreement with Affymetrix UK, Biolytix said last week.
 
The company plans to use the GeneChip platform to offer exon and tiling arrays and SNP genotyping and gene-mapping arrays that could be used in transcriptome mapping, gene regulation, genome-wide SNP mapping, and resequencing.
 
Financial terms of the agreement were not released.
 

 
Georgia Tech Installs BioForce Nanosciences' Molecular Printing System
 
The Georgia Institute of Technology has purchased a Nano eNabler molecular printing system from BioForce Nanosciences, the company said last week.
 
BioForce said the Nano eNabler can be used in patterning and cell adhesion, for printing proteins to direct neural cell growth, and in sensor functionalization.
 
The company sold the Nano eNabler to Georgia Tech through a pilot program that involved placing the tool in 20 biomedical and life sciences facilities for trial use.
 
Curtis Mosher, vice president of R&D at BioForce, said Georgia Tech is using the system to place polymers on diagnostic sensors in “precise patterns” to create sensors with applications in personalized medicine, environmental monitoring, and remote chemical analysis.
 
Financial terms of the agreement were not released.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.